State of Biohacking Products

The Biohacking Standard · catalog cross-section

Only 33 of 6,101 scored products — 0.54% — reach Elite.

Vyvata scored every listed SKU 0–100 on a public six-dimension rubric. Elite is 85–100. In the 7 October 2026 catalog, 33 products clear that bar — about 1 in 185. The median score is 55. Rejected products stay listed.

Current edition: Q3 2026 State of Biohacking Products (catalog generated 7 October 2026, n=6,101). Attribution: Vyvata / The Biohacking Standard. Brands cannot pay for inclusion, score, or placement.

Key findings from Q3 2026

  1. Only 0.54% (33 of 6,101) scored products reach Elite (85–100).

  2. 40.3% (2,457 of 6,101) of the catalog is Rejected and remains listed.

  3. 61.7% (37 of 60) sleep-optimization products are Rejected — the highest Rejected share of any category.

  4. Products matched to conglomerate parents average 71.63 (n=147) versus 60.33 for matched independent brands (n=75).

  5. The median Evidence score among 96 wearables on the six-dimension rubric is 20/100.

How to cite

Vyvata, “Q3 2026 State of Biohacking Products,” The Biohacking Standard, catalog generated 7 October 2026, n=6,101. https://vyvata.com/pages/state-of-biohacking-q3-2026

Read the dated tables, auto-fail frequencies, and FAQ on the Q3 2026 report. Scoring rules live on Methodology. Parent matches sit on Who owns your supplement brands.